Nathan Rice

Stock Analyst at Piper Sandler

(2.78)
# 2,008
Out of 5,032 analysts
56
Total ratings
45.71%
Success rate
8.45%
Average return

Stocks Rated by Nathan Rice

Merchants Bancorp
Jul 30, 2025
Maintains: Overweight
Price Target: $42$41
Current: $30.91
Upside: +32.64%
First Mid Bancshares
Jul 28, 2025
Maintains: Overweight
Price Target: $47$49
Current: $35.53
Upside: +37.91%
Bank First
Jul 21, 2025
Maintains: Neutral
Price Target: $115$137
Current: $120.95
Upside: +13.27%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $26.19
Upside: +29.82%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $82.52
Upside: -10.32%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $125.00
Upside: -32.80%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $130.45
Upside: +51.02%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $21.42
Upside: -57.98%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $635.40
Upside: -31.54%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $299.27
Upside: -22.14%
Initiates: Neutral
Price Target: $83
Current: $35.27
Upside: +135.33%
Initiates: Overweight
Price Target: $15
Current: $17.07
Upside: -12.13%